COMPASS Pathways (NASDAQ:CMPS) Price Target Lowered to $45.00 at HC Wainwright

COMPASS Pathways (NASDAQ:CMPS) had its target price lowered by HC Wainwright from $60.00 to $45.00 in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on CMPS. Maxim Group cut their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $30.60.

COMPASS Pathways Stock Up 4.0 %

NASDAQ:CMPS opened at $4.42 on Thursday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75. The company has a market cap of $302.42 million, a PE ratio of -2.01 and a beta of 2.28. The company’s 50 day moving average is $4.09 and its two-hundred day moving average is $5.49.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMPS. Polar Asset Management Partners Inc. grew its position in COMPASS Pathways by 83.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after purchasing an additional 258,000 shares during the period. Sio Capital Management LLC boosted its stake in shares of COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after buying an additional 621,222 shares during the last quarter. Walleye Capital LLC acquired a new stake in COMPASS Pathways during the third quarter worth about $2,126,000. Acuta Capital Partners LLC purchased a new position in COMPASS Pathways during the third quarter valued at approximately $2,435,000. Finally, Geode Capital Management LLC lifted its holdings in COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after acquiring an additional 25,970 shares during the period. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.